A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Recruiting now Phase 3 NCT07318558
Run by Merck Sharp & Dohme LLC · for 18 and older · Women
What this study is about
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Who can join (things the study team will check)
The main inclusion criteria include but are not limited to the following: * Has diagnosis of FIGO 2014 Stage III or Stage IV, histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with one of the following histologies: high-grade serous, high-grade endometrioid, clear cell carcinoma, or malignant mixed Müllerian tumour with a high-grade serous component. Tumors reported as Grade 2 may be enrolled only if predominately (\>50%) Grade 3 features are present. * Has completed primary debulking surgery or interval debulking surgery. * Has completed first-line (1L) platinum-based chemotherapy, with a response of stable disease, partial response, complete response or no evidence of disease per protocol. * Has provided tumor tissue that is not previously irradiated. * Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if diagnosed with HIV * Has undetectable hepatitis B virus (HBV) viral load and received HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive. * Has undetectable hepatitis C virus (HCV) viral load if has a history of HCV infection. The main exclusion criteria include but are not limited to …
Where this trial is running
- University of Alabama - Birmingham ( Site 0058), Birmingham, Alabama, United States
- John Muir Health Cancer Center ( Site 0069), Walnut Creek, California, United States
- Mount Sinai Cancer Center ( Site 0029), Miami Beach, Florida, United States
- Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085), Orlando, Florida, United States
- Winship Cancer Institute of Emory University ( Site 0037), Atlanta, Georgia, United States
- Illinois Cancer Specialists (ICS) ( Site 8009), Arlington Heights, Illinois, United States
- Parkview Research Center at Parkview Regional Medical Center ( Site 0055), Fort Wayne, Indiana, United States
- Franciscan Health Indianapolis ( Site 0081), Indianapolis, Indiana, United States
- Women's Cancer Care ( Site 0018), Covington, Louisiana, United States
- Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0060), Scarborough, Maine, United States
- Maryland Oncology Hematology, P.A. ( Site 8002), Columbia, Maryland, United States
- Nebraska Methodist Hospital ( Site 0004), Omaha, Nebraska, United States
+ 149 more sites.
Who to contact
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07318558.
Verify everything on the official ClinicalTrials.gov record. Page updated September 2026.